PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

Merck calls ACIP’s pneumococcal recommendation a ‘missed opportunity,’ advocates for expanding age group

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 29, 2024

FDA adcomm votes in favor of Geron’s anemia drug for cancer patients despite questions on risk

Members of the FDA’s Oncologic Drugs Advisory Committee voted 12 to 2 on Thursday that the benefits of Geron’s imetelstat outweigh safety risks for the

March 15, 2024

When is a Wall Street disappointment ‘good enough’ for the FDA?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian

October 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.